Keywords: Amgen, First-quarter 2011 financial results
Amgen sees 1st-qtr 2011 net dip 3.4%, as anemia drug sales fall
Article | 21 April 2011
USA-based Amgen (Nasdaq: AMGN) said net income for the first quarter of 2011 dipped 3.4% to $1.13 billion, or $1.20. Earnings excluding one-time items ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
